APGE icon

Apogee Therapeutics

47.71 USD
+0.69
1.47%
At close Dec 20, 4:00 PM EST
After hours
47.71
+0.00
0.00%
1 day
1.47%
5 days
4.06%
1 month
5.93%
3 months
-18.35%
6 months
25.39%
Year to date
67.34%
1 year
92.46%
5 years
124.73%
10 years
124.73%
 

About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.

Employees: 91

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

75% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 7 (+3) [Q3]

54% more capital invested

Capital invested by funds: $2.14B [Q2] → $3.29B (+$1.15B) [Q3]

3.71% more ownership

Funds ownership: 120.94% [Q2] → 124.66% (+3.71%) [Q3]

0% more funds holding

Funds holding: 139 [Q2] → 139 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 26

2% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 47

83% less call options, than puts

Call options by funds: $2.65M | Put options by funds: $15.2M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$89
87%
upside
Avg. target
$90
88%
upside
High target
$90
89%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
David Nierengarten
38% 1-year accuracy
49 / 128 met price target
89%upside
$90
Outperform
Maintained
2 Dec 2024
Canaccord Genuity
Edward Nash
72% 1-year accuracy
13 / 18 met price target
87%upside
$89
Buy
Initiated
25 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Neutral
GlobeNewsWire
3 weeks ago
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET.
Apogee Therapeutics Announces Agenda for Virtual R&D Day
Neutral
GlobeNewsWire
1 month ago
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Positive
Seeking Alpha
1 month ago
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's strong cash runway and multiple upcoming catalysts, including Phase 2 results for APG777, justify its current valuation premium.
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Neutral
GlobeNewsWire
1 month ago
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management will participate at the following investor conferences.
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
Neutral
GlobeNewsWire
2 months ago
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
Neutral
GlobeNewsWire
3 months ago
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that members of management, will participate in a fireside chat at the Stifel 2024 Immunology and Inflammation Summit on Wednesday, September 18, 2024 at 12:30 p.m. E.T. / 9:30 a.m. P.T.
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
Neutral
GlobeNewsWire
3 months ago
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease and other I&I indications, today announced the appointment of Jeff S. Hartness as Chief Commercial Officer. Mr. Hartness has an extensive track record in commercial and corporate leadership, bringing more than 25 years of experience in the biotech industry focused on product launches, market access strategy, pricing and policy.
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
Neutral
GlobeNewsWire
4 months ago
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and across I&I diseases SAN FRANCISCO and WALTHAM, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG990, a novel, subcutaneous (SQ) half-life extended monoclonal antibody targeting OX40L, which is being developed initially as a treatment for people living with AD.
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Neutral
GlobeNewsWire
4 months ago
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
Charts implemented using Lightweight Charts™